QuidelOrtho Corporation – NASDAQ:QDEL
QuidelOrtho stock price today
$26.745
-17.50
-39.56%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
QuidelOrtho stock price monthly change
+36.66%
month
QuidelOrtho stock price quarterly change
+36.66%
quarter
QuidelOrtho stock price yearly change
-41.34%
year
QuidelOrtho key metrics
Market Cap | 2.97B |
Enterprise value | 8.40B |
P/E | 9.53 |
EV/Sales | 2.57 |
EV/EBITDA | 7.69 |
Price/Sales | 1.86 |
Price/Book | 1.23 |
PEG ratio | -0.22 |
EPS | -26.39 |
Revenue | 2.86B |
EBITDA | 308.7M |
Income | -1.76B |
Revenue Q/Q | -16.12% |
Revenue Y/Y | -7.98% |
Profit margin | 16.8% |
Oper. margin | 25.83% |
Gross margin | 78.15% |
EBIT margin | 25.83% |
EBITDA margin | 10.79% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeQuidelOrtho stock price history
QuidelOrtho stock forecast
QuidelOrtho financial statements
| Jul 2023 | 665.1M | -53.2M | -8% |
|---|---|---|---|
| Oct 2023 | 744M | -12.7M | -1.71% |
| Dec 2023 | 742.6M | 7M | 0.94% |
| Mar 2024 | 709.7M | -1.70B | -240.38% |
| Sep 2025 | 703.06M | 49.46M | 7.04% |
|---|---|---|---|
| Oct 2025 | 678.98M | 44.86M | 6.61% |
| Dec 2025 | 767.57M | 97.36M | 12.68% |
| Mar 2026 | 753M | 71.33M | 9.47% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-02 | -0.925 | 1.85 |
|---|---|---|
| 2023-01-01 | 0.37 | 0.4529 |
| 2023-02-15 | 1.35 | 1.76 |
| Jul 2023 | 8550300000 | 3.54B | 41.49% |
|---|---|---|---|
| Oct 2023 | 8539100000 | 3.57B | 41.84% |
| Dec 2023 | 8563100000 | 3.55B | 41.54% |
| Mar 2024 | 6703300000 | 3.39B | 50.66% |
| Jul 2023 | -30.6M | -42.3M | -99.7M |
|---|---|---|---|
| Oct 2023 | 41.5M | -21.3M | -48.7M |
| Dec 2023 | 80.4M | -55.1M | -57.8M |
| Mar 2024 | -700K | -20.2M | -18.5M |
QuidelOrtho alternative data
| Aug 2023 | 7,000 |
|---|---|
| Sep 2023 | 7,000 |
| Oct 2023 | 7,000 |
| Nov 2023 | 7,000 |
| Dec 2023 | 7,000 |
| Jan 2024 | 7,000 |
| Feb 2024 | 7,000 |
| Mar 2024 | 7,100 |
| Apr 2024 | 7,100 |
| May 2024 | 7,100 |
| Jun 2024 | 7,100 |
| Jul 2024 | 7,100 |
QuidelOrtho other data
100.00%
+12.97%
of QDEL is owned by hedge funds
335
-5
58.15M
+21.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 2150 | 0 |
| Jun 2024 | 0 | 208497 |
| Jul 2024 | 0 | 2094229 |
| Aug 2024 | 0 | 868565 |
| Nov 2024 | 0 | 8260183 |
| Dec 2024 | 6033 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BLASER BRIAN J. officer: President and CEO | Common Stock | 6,033 | $41.42 | $249,881 | ||
Option | HODGES MICHELLE A. officer: Chief Legal Officer | Restricted Stock Units | 238 | N/A | N/A | ||
Sale | CARLYLE GROUP INC. 10 percent owner | Common Stock | 8,260,183 | $35.31 | $291,700,102 | ||
Option | HODGES MICHELLE A. officer: Chief Legal Officer | Restricted Stock Units | 3,970 | N/A | N/A | ||
Option | BUJARSKI ROBERT JOSEPH officer: EVP & COO | Restricted Stock Units | 390 | N/A | N/A | ||
Option | HODGES MICHELLE A. officer: SVP, General Counsel | Restricted Stock Units | 390 | N/A | N/A | ||
Option | BUJARSKI ROBERT JOSEPH officer: EVP & COO | Restricted Stock Units | 314 | N/A | N/A | ||
Sale | CARLYLE GROUP INC. 10 percent owner | Common Stock | 6,344 | $40.81 | $258,873 | ||
Sale | CARLYLE GROUP INC. 10 percent owner | Common Stock | 67,790 | $41.6 | $2,820,132 | ||
Sale | CARLYLE GROUP INC. 10 percent owner | Common Stock | 200 | $38.97 | $7,795 |
| Patent |
|---|
Application Filling date: 4 Mar 2022 Issue date: 16 Jun 2022 |
Application Filling date: 14 Dec 2021 Issue date: 7 Apr 2022 |
Application Filling date: 15 Jan 2019 Issue date: 3 Mar 2022 |
Application IMMUNOASSAY TEST DEVICE WITH TWO FLUID FLOW PATHS FOR DETECTION AND DIFFERENTIATION OF TWO OR MORE ANALYTES Filling date: 24 Aug 2021 Issue date: 23 Dec 2021 |
Application Filling date: 26 Aug 2021 Issue date: 16 Dec 2021 |
Application Filling date: 28 May 2021 Issue date: 2 Dec 2021 |
Application Filling date: 28 May 2021 Issue date: 2 Dec 2021 |
Application Filling date: 13 May 2021 Issue date: 18 Nov 2021 |
Grant Filling date: 8 Mar 2019 Issue date: 28 Sep 2021 |
Grant Utility: Immunoassay test device with two fluid flow paths for detection and differentiation of two or more analytes Filling date: 25 Aug 2016 Issue date: 28 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 13 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
QuidelOrtho: Margins Normalizing Lower But Stable
QuidelOrtho: Thoughts After A Tough Time
QuidelOrtho: Mapping A Future As Covid Revenues Move To Endemic Phase
QuidelOrtho: A Tough Call To Make Right Now
QuidelOrtho: 5x Earnings Is Borderline Offensive, Rate Buy At 20x
InMode: High Growth, High Margin Medical Device Company On Sale
QuidelOrtho: Robust Pipeline Of Labs Products Ahead
QuidelOrtho: Gets Covid Test Win, Ortho Cost Synergies Improve
QuidelOrtho: Fundamentals Remain, Upbeat Financials
-
What's the price of QuidelOrtho stock today?
One share of QuidelOrtho stock can currently be purchased for approximately $26.75.
-
When is QuidelOrtho's next earnings date?
Unfortunately, QuidelOrtho's (QDEL) next earnings date is currently unknown.
-
Does QuidelOrtho pay dividends?
No, QuidelOrtho does not pay dividends.
-
How much money does QuidelOrtho make?
QuidelOrtho has a market capitalization of 2.97B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 76.49% to 3B US dollars. QuidelOrtho made a loss 10.1M US dollars in net income (profit) last year or $1.76 on an earnings per share basis.
-
What is QuidelOrtho's stock symbol?
QuidelOrtho Corporation is traded on the NASDAQ under the ticker symbol "QDEL".
-
What is QuidelOrtho's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of QuidelOrtho?
Shares of QuidelOrtho can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are QuidelOrtho's key executives?
QuidelOrtho's management team includes the following people:
- Mr. Douglas C. Bryant Pres, Chief Executive Officer & Director(age: 67, pay: $1,980,000)
- Mr. Robert J. Bujarski Chief Operating Officer(age: 57, pay: $1,060,000)
- Mr. Randall J. Steward Chief Financial Officer(age: 71, pay: $1,010,000)
- Dr. Werner Kroll Senior Vice President of R&D(age: 68, pay: $860,090)
- Mr. Ratan S. Borkar Senior Vice President of International Commercial Operations(age: 51, pay: $803,160)
-
How many employees does QuidelOrtho have?
As Jul 2024, QuidelOrtho employs 7,100 workers.
-
When QuidelOrtho went public?
QuidelOrtho Corporation is publicly traded company for more then 34 years since IPO on 1 Feb 1991.
-
What is QuidelOrtho's official website?
The official website for QuidelOrtho is quidelortho.com.
-
Where are QuidelOrtho's headquarters?
QuidelOrtho is headquartered at 9975 Summers Ridge Road, San Diego, CA.
-
How can i contact QuidelOrtho?
QuidelOrtho's mailing address is 9975 Summers Ridge Road, San Diego, CA and company can be reached via phone at 858 552 1100.
QuidelOrtho company profile:
QuidelOrtho Corporation
quidelortho.comExchange:
NASDAQ
Full time employees:
7,100
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
9975 Summers Ridge Road
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001906324
ISIN: US2197981051
CUSIP: 219798105
